William H. Hildebrand

Pure Protein LLC specializes in immunology tools for diagnostics, drug and vaccine development, and high-yield protein production. It operates as a biopharmaceutical company, produces soluble human leukocyte antigen (sHLA) proteins and custom products in various human and animal cell lines. The firm provides sHLA class I and II proteins for use in transplantation, drug target discovery, and bio-therapeutic development, as well as diagnostic and therapeutic reagents for use in immunology research and development. The company was founded by William Hildebrand in 1999 and is headquartered in Austin, TX.

Pure MHC LLC provides diagnostics and therapeutics technology services. It offers epitope discovery solution where it identifies peptide epitopes that are upregulated in the affected state and validated as ligands presented by human leukocyte antigen (HLA) molecules and T cell receptor mimics (TCRms) technology, monoclonal antibodies that function like T-cell receptor. The firm also provides regulatory compliance support and existing target validation and tissue distribution services. The company was founded by William Hildebrand in 2013 and is headquartered in Austin, TX.

MHC Biologics, LLC, an emerging biotechnology company, has developed a unique and proprietary portfolio of breakthrough technologies that can be used in the development and design of novel therapeutics, including therapeutic vaccines for cancer and other diseases. MHC Biologics has been founded to focus on clinical applications of a suite of immunology tools developed in the laboratories of Dr. Jon Weidanz, Texas Tech University Pharmacy School and Receptor Logic, Ltd., and Dr. William Hildebrand, Oklahoma University Health Science Center and Pure Vaccine Solutions, LLC. These technology 'tools' can be utilized for immunology-based cancer diagnosis and treatment. Funded and managed by life sciences venture firm, Emergent Technologies, Inc., MHC Biologics is actively seeking commercialization partners. MHC Biologics offers breakthrough therapeutic antibody technology targeting a new class of disease biomarkers - peptides presented by the Major Histocompatibility Complex (MHC; also known as human leukocyte antigen, or HLA). These peptides are derived from intracellular processing of tumor or viral proteins and are presented as complexes with MHC proteins on antigen-presenting cells. MHC Biologics' unique antibody strategy exhibits disease-specific binding and efficacy in preclinical studies as a cancer therapeutic modality, providing next-generation products for treatment of cancer and other important diseases.